Heavy metal--rely on gut feelings: novel diagnostic approach to test drug compliance in patients with lanthanum intake

Authors:

Abstract
According to several guidelines, a high calcium–phosphate product (>4.46 mmol/l) is a major cause of cardiovascular morbidity and mortality in patients with end-stage renal disease (ESRD) [ 1 ]. Hyperphosphataemia management is therapeutically tedious, largely because of the number of tablets patients must ingest. Monitoring compliance to an anti-phosphataemic regimen is bereft of reliable signs. Patients regularly swear faithful adherence to the hated regimen, while their laboratory values suggest otherwise. A reliable indicator of compliance has not been available until now. Serendipity served us a solution to this knotty problem. Lanthanum carbonate is a novel compound prescribed for phosphate binding in ESRD patients. The drug is calcium-and aluminum-free. Prandial intake of lanthanum carbonate is generally well tolerated. Lanthanum is poorly absorbed systemically and therefore does not accumulate [ 2 ]. The material appears to be non-toxic. Extensive animal studies have been performed and human experience thus far supports this contention [ 3 ].